心絞痛治療市場規模、佔有率和成長分析：按藥物類別、類型、給藥途徑、通路和地區分類－2026-2033年產業預測

2024 年全球心絞痛治療市場價值為 85.2 億美元，預計到 2033 年將從 2025 年的 89.9 億美元成長至 138.5 億美元，預測期（2026-2033 年）的複合年成長率為 5.52%。

全球心絞痛治療市場的主要驅動力是人口成長和老化，以及缺血性心臟疾病發病率的上升，這導致對症治療和預防性治療的需求不斷成長。該市場涵蓋多種治療方案，包括短效和長效硝酸酯類藥物、 BETA阻斷劑和鈣通道阻斷劑，以及蘭諾嗪和Ivabradine等新型藥物，所有這些藥物對於改善患者的生活品質和減少住院次數都至關重要。此外，新興市場學名藥的興起和醫療保健覆蓋範圍的擴大正在推動銷售量成長並促進藥物差異化，因為昂貴的品牌藥失去專利保護期會導致價格下降和處方機會增加。人工智慧在藥物研發中的應用正在加速標靶識別、分子設計和臨床試驗流程的簡化，重點在於探索改善長期症狀管理的新機制。

全球心絞痛治療市場的成長要素

全球心絞痛治療市場的主要促進因素之一是心血管疾病盛行率的不斷上升，這推動了對有效治療方法日益成長的需求。由於不良飲食、缺乏運動和壓力增加等生活方式的改變，越來越多的人出現心絞痛症狀，這些改變也會導致心臟相關疾病。患者數量的增加促使人們需要改進藥物治療，以控制疼痛並提高生活品質。此外，持續進行的創新製劑和標靶治療研發工作也進一步加速了市場成長，因為醫療專業人員正在尋求新的解決方案來應對這一重要的健康問題。

全球心絞痛治療市場的限制因素

全球心絞痛治療市場的主要限制因素之一是人們越來越關注非藥物療法，例如生活方式改善以及血管成形術和支架置入術等介入性治療。隨著醫護人員和患者越來越意識到健康習慣（例如飲食、運動和壓力管理）的益處，他們對藥物治療的依賴性可能會降低。這種對替代治療方法的偏好增加可能會限制對心絞痛藥物的需求，從而影響整體市場成長。此外，持續藥物治療的高昂費用也可能使患者不願堅持處方治療。

全球心絞痛治療藥物市場趨勢

全球心絞痛治療市場正經歷著向個人化醫療的重大轉變，從根本上改變了心絞痛的治療方式。這一趨勢的驅動力源於基於生物標記的分層和藥物基因體學的進步，使臨床醫生能夠制定針對個別患者特徵和合併症的治療方案，從而提高治療反應預測的準確性並最大限度地減少試驗法。診斷試劑製造商、技術公司和製藥研發公司之間的合作正在加速伴隨診斷和標靶治療的交付。隨著支付方和醫療服務提供者日益重視精準醫療以追求更好的患者療效，對小眾治療方法和簡化的臨床決策支援機制的投資也在不斷增加，從而促進了各種醫療機構中個性化處方流程的實施。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球心絞痛治療藥物市場規模：依藥物類別分類

• 硝酸鹽
• BETA受體阻斷劑
• 鈣離子通道阻斷劑
• 蘭諾嗪（Lanexa）
• Ivabradine

全球心絞痛藥物市場規模：按類型分類

• 穩定性心絞痛
• 不穩定型心絞痛
• 血管痙攣性（變異型）心絞痛

全球心絞痛治療藥物市場規模：依給藥途徑分類

• 口服
• 舌下
• 經皮吸收

全球心絞痛藥物市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 線上

全球心絞痛治療藥物市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer Inc.
• AstraZeneca
• Novartis AG
• Gilead Sciences（Ranexa）
• Servier Laboratories（Ivabradine）
• Bayer AG
• Sanofi SA
• Merck & Co.
• GlaxoSmithKline
• Teva Pharmaceutical
• Mylan（Viatris）
• Watson Pharmaceuticals
• Forest Laboratories（Allergan）
• Actavis（Allergan）
• Noven Pharmaceuticals
• Par Pharmaceutical
• Lannett Company
• Hi-Tech Pharmacal
• Cadila Healthcare
• Intas Pharmaceuticals

結論與建議

Global Angina Pectoris Drugs Market size was valued at USD 8.52 Billion in 2024 and is poised to grow from USD 8.99 Billion in 2025 to USD 13.85 Billion by 2033, growing at a CAGR of 5.52% during the forecast period (2026-2033).

The global angina pectoris drugs market is primarily fueled by an increasing and aging population alongside the rising incidence of ischemic heart disease, leading to heightened demand for both symptomatic and preventive treatments. The market encompasses various therapeutic options, including short- and long-acting nitrates, beta blockers, calcium channel blockers, as well as newer agents like ranolazine and ivabradine, all crucial for improving patient quality of life and reducing hospitalizations. Additionally, the rise of generics and expanded healthcare access in emerging markets drive volume growth and enable differentiation, as the loss of exclusivity of costly brand-name drugs results in reduced prices and broader prescribing opportunities. AI's integration into drug discovery enhances target identification, molecule design, and trial efficiency, focusing on novel mechanisms for better long-term symptom management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Angina Pectoris Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Angina Pectoris Drugs Market Segments Analysis

Global angina pectoris drugs market is segmented by drug class, type, route, distribution and region. Based on drug class, the market is segmented into Nitrates, Beta-Blockers, Calcium Channel Blockers, Ranolazine (Ranexa) and Ivabradine. Based on type, the market is segmented into Stable Angina, Unstable Angina and Vasospastic (Variant) Angina. Based on route, the market is segmented into Oral, Sublingual, and Transdermal. Based on distribution, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Angina Pectoris Drugs Market

One of the key market drivers for the global angina pectoris drugs market is the increasing prevalence of cardiovascular diseases, which has led to a rising demand for effective treatment options. As lifestyle changes, such as poor diet, physical inactivity, and increased stress, contribute to heart-related conditions, more individuals are experiencing symptoms of angina pectoris. This growing patient population necessitates advancements in pharmacological therapies to manage pain and improve quality of life. Additionally, ongoing research and development efforts focused on innovative drug formulations and targeted therapies further accelerate market growth, as healthcare providers seek novel solutions to address this significant health concern.

Restraints in the Global Angina Pectoris Drugs Market

One key market restraint for the global angina pectoris drugs market is the increasing focus on non-pharmacological treatment options, such as lifestyle modifications and interventional procedures like angioplasty and stenting. As healthcare providers and patients become more aware of the benefits of adopting healthy habits, including diet, exercise, and stress management, reliance on medication may decline. This growing preference for alternative treatment methods can limit the demand for angina pectoris drugs, thereby impacting overall market growth. Furthermore, the high costs associated with ongoing medication therapies may also deter patients from adhering to prescribed treatments.

Market Trends of the Global Angina Pectoris Drugs Market

The Global Angina Pectoris Drugs market is witnessing a significant shift towards personalized therapeutics, fundamentally transforming how angina is managed. This trend is driven by advancements in biomarker-driven stratification and pharmacogenomic insights, enabling clinicians to devise treatment plans tailored to individual patient profiles and comorbidities, thus enhancing prediction of therapeutic responses and minimizing trial-and-error approaches. Collaborative efforts among diagnostics companies, technology firms, and pharmaceutical developers are accelerating the availability of companion diagnostics and targeted formulations. As payers and healthcare providers increasingly favor precision medicine for better patient outcomes, investment in niche therapies and streamlined clinical decision support mechanisms is on the rise, fostering individualized prescribing pathways across various healthcare settings.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Angina Pectoris Drugs Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Nitrates
• Beta-Blockers
• Calcium Channel Blockers
• Ranolazine (Ranexa)
• Ivabradine

Global Angina Pectoris Drugs Market Size by Type & CAGR (2026-2033)

• Market Overview
• Stable Angina
• Unstable Angina
• Vasospastic (Variant) Angina

Global Angina Pectoris Drugs Market Size by Route & CAGR (2026-2033)

• Market Overview
• Oral
• Sublingual
• Transdermal

Global Angina Pectoris Drugs Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online

Global Angina Pectoris Drugs Market Size & CAGR (2026-2033)

• North America (Drug Class, Type, Route, Distribution)
  • US
  • Canada
• Europe (Drug Class, Type, Route, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Type, Route, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Type, Route, Distribution)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Type, Route, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (Ranexa)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Servier Laboratories (Ivabradine)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Watson Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Forest Laboratories (Allergan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Actavis (Allergan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Noven Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Par Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lannett Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hi-Tech Pharmacal
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations